Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1

ALN-GO1-006

The purpose of this study is to provide expanded access to lumasiran for adults and pediatric patients with Primary Hyperoxaluria Type 1 (PH1),

-1

Inclusion Criteria: * Documented diagnosis of Primary Hyperoxaluria Type 1 Exclusion Criteria: * Clinically significant health concerns (with the exception of PH1) * Received an investigational agent within 30 days before the first dose of lumasiran or are in follow-up of another clinical study * Previously or currently participating in lumasiran clinical study * History of liver transplant

{'studyType': 'EXPANDED_ACCESS', 'nPtrsToThisExpAccNctId': 2, 'expandedAccessTypes': {'individual': True, 'treatment': True}}

2024-02-16